Improving the catalytic performance of Co/BaCeO catalyst for ammonia synthesis by Y-modification of the perovskite-type support.

Y-modified perovskite-type oxides BaCe Y O ( = 0-0.30) were synthesised and used as supports for cobalt catalysts. The influence of yttrium content on the properties of the support and catalyst performance in the ammonia synthesis reaction was examined using PXRD, STEM-EDX, and sorption techniques (N physisorption, H-TPD, CO-TPD).

Elucidating the role of potassium addition on the surface chemistry and catalytic properties of cobalt catalysts for ammonia synthesis.

The ammonia synthesis process produces millions of tons of ammonia annually needed for the production of fertilisers, making it the second most produced chemical worldwide. Although this process has been optimised extensively, it still consumes large amounts of energy (around 2% of global energy consumption), making it essential to improve its efficiency. To accelerate this improvement, research on catalysts is necessary.

Antimicrobial glycoprotein 2 (GP2) in gallstones, bile fluid and peribiliary glands of patients with primary sclerosing cholangitis.

Background: Glycoprotein-2 (GP2) IgA is a predictor of disease severity in primary sclerosing cholangitis (PSC). We examined GP2's occurrence in the biliary tract, the site of inflammation.

Methods: GP2 was analyzed using ELISA, immunoblotting, mass spectrometry, and immunohistochemistry.

Routine End-ischemic Hypothermic Oxygenated Machine Perfusion in Liver Transplantation From Donors After Brain Death: A Randomized Controlled Trial.

Objective: To assess whether end-ischemic hypothermic oxygenated machine perfusion (HOPE) is superior to static cold storage (SCS) in preserving livers procured from donors after brain death (DBD).

Background: There is increasing evidence of the benefits of HOPE in liver transplantation, but predominantly in the setting of high-risk donors.

Methods: In this randomized clinical trial, livers procured from DBDs were randomly assigned to either end-ischemic dual HOPE for at least 2 hours or SCS (1:3 allocation ratio).